Investors

This section of the website provides financial reports, investor presentations, information on key corporate transactions and much more.

We strive to be transparent, relevant and accurate in presenting our financial information, in order to inform our stakeholders of the company’s operations and financial position.

If you have any questions, please don’t hesitate to contact us at investors@c-rad.com
Svensk version här

Sign up to our newsletter to keep up to date with investor news

Five reasons to invest in C-RAD

  • Contributing to improved cancer care and ultimately saving human life
  • Several factors point towards surface tracking becoming standard of care – which will unleash a vast market potential for C-RAD with exponential revenue growth
  • C-RAD has a proven and recognized product
  • C-RAD has comprehensive market access with a direct sales force, distributors, and direct cooperation with OEM-vendors
  • C-RAD has a stable financial platform – profitable growth, debt free and +100 MSEK in cash
Learn more

Press releases

2023-02-15 16:35 Nordstrahl, en ledande strålbehandlingsklinik i Tyskland, väljer C-RADs innovativa SGRT-lösning News Corporate Information Sales Order Swedish IR
2023-02-15 16:35 Nordstrahl, a leading radiotherapy practice in Germany, selects C-RAD’s innovative SGRT solution News Corporate Information Sales Order English IR
2023-02-02 13:01 C-RAD nomination committee's proposal for board of directors. Kristina Willgård is proposed as new chairman. News Corporate Information Nomination Committee English Regulatory Listing Regulation IR
2023-02-02 13:01 Valberedningens förslag till ny styrelse i C-RAD. Kristina Willgård föreslås till ny ordförande. News Corporate Information Nomination Committee Swedish Regulatory Listing Regulation IR
2023-01-26 08:30 Stark orderingång, försäljning och kassaflöde i fjärde kvartalet avslutade 2022 News Swedish Regulatory MAR Report Interim Yearend IR
2023-01-26 08:30 Strong order intake, revenues and cash flow in Q4 to end the financial year 2022 News English Regulatory MAR Report Interim Yearend IR

Shares & stock

Please feel free to contact us regarding investments or other financial questions

If you have any questions, please don’t hesitate to contact us